As the pharmaceutical industry moves beyond small molecule drugs into biologics and gene therapies, USP NF 47 adapts by introducing new monographs for complex substances. This includes updated standards for peptide therapeutics and advanced delivery systems, ensuring that cutting-edge treatments are held to the same rigorous safety standards as traditional tablets.
: Continued alignment with modern testing methods (like ICP-OES/ICP-MS) that have long since replaced outdated heavy metal tests like the obsolete Why Staying Current Matters usp nf 47
Action item: Review the "List of Adopted Monographs" on the USP website to see if your products are affected. As the pharmaceutical industry moves beyond small molecule
: With the rise of complex therapies, USP 47 includes updated performance standards for monoclonal antibodies (mAbs) to ensure analytical consistency. Elastomeric Components : Revisions to general chapters like : With the rise of complex therapies, USP
is the 2024 edition of the United States Pharmacopeia and the National Formulary (USP–NF). It serves as the definitive set of official quality standards for medicines, dosage forms, drug substances, excipients, and dietary supplements manufactured or marketed in the United States.